Daniel E. Ryweck - 23 May 2025 Form 4 Insider Report for Silo Pharma, Inc. (SILO)

Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
4
Accepted by SEC
27 May 2025, 19:02:50 UTC
Prior SEC filing
26 May 2023
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Daniel E. Ryweck

Key filing fact

Daniel E. Ryweck filed Form 4 for Silo Pharma, Inc. (SILO) on 27 May 2025.

Key facts

  • This page summarizes Daniel E. Ryweck's Form 4 filing for Silo Pharma, Inc. (SILO).
  • 1 reported transaction and 1 derivative row are listed below.
  • Accepted by SEC: 27 May 2025, 19:02.

Change

  • Previous filing in this sequence was filed on 26 May 2023.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001652799 Primary reporting owner

Ryweck Daniel E.

Relationship
Chief Financial Officer
Address
C/O SILO PHARMA, INC., 677 N. WASHINGTON BOULEVARD, SARASOTA
Signature
/s/ Daniel E. Ryweck
Signature date
27 May 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

SILO transaction Derivative

Options (right to buy)

Award

Transaction value
$0
Shares
+50,000
Change %
+1000%
Price
$0.000000
Shares after
55,000
Date
23 May 2025
Ownership
Direct
Underlying class
Common Stock
Underlying amount
50,000
Exercise price
$0.4290
Footnotes
F1
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The options were issued pursuant to the Issuer's 2020 Omnibus Equity Incentive Plan and one hundred percent (100%) of the shares subject to the option shall vest on the one (1)-year anniversary of the date of grant.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .